# A Study of BMS-986224 in Healthy Subjects and Heart Failure Patients With Reduced Ejection Fraction

> **NCT03281122** · PHASE1 · TERMINATED · sponsor: **Bristol-Myers Squibb** · enrollment: 199 (actual)

## Conditions studied

- Heart Failure

## Interventions

- **DRUG:** Placebo
- **DRUG:** BMS-986224

## Key facts

- **NCT ID:** NCT03281122
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-09-22
- **Primary completion:** 2019-04-17
- **Final completion:** 2019-04-17
- **Target enrollment:** 199 (ACTUAL)
- **Why stopped:** Business objectives have changed
- **Last updated:** 2021-02-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03281122

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03281122, "A Study of BMS-986224 in Healthy Subjects and Heart Failure Patients With Reduced Ejection Fraction". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03281122. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*